Bortezomib: Proteasome Inhibition as a Novel Mechanism of Cancer Therapy-Implications for Hematological Malignancies

Title: Bortezomib: Proteasome Inhibition as a Novel Mechanism of Cancer Therapy-Implications for Hematological Malignancies

Volume: 4 Issue: 2

Author(s): Joesph Mikhael and Hong Chang

Affiliation:

Keywords: Proteasome inhibitor, Bortezomib, Multiple myeloma, Clinical trial, Cancer

Abstract: The proteasome is a multicatalytic proteinase complex that is responsible for protein turnover through the ubiquitin-proteasome pathway. Bortezomib is the first drug to act as a proteasome inhibitor, and has yielded impressive anticancer effects in phase III trials in multiple myeloma. Its role in other hematological malignancies is being evaluated. Proteasome inhibition, therefore, represents a novel mechanism for anticancer therapy.

Cite this article as:

Mikhael Joesph and Chang Hong, Bortezomib: Proteasome Inhibition as a Novel Mechanism of Cancer Therapy-Implications for Hematological Malignancies, Letters in Drug Design & Discovery 2007; 4 (2) . https://dx.doi.org/10.2174/157018007779422541